At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Sodium-glucose transport-2 (SGLT-2) inhibitors (drug), Standard medical treatment (other)
- How long the study runs
- Study runs about 34 months (dates as stated)
- About the drug or intervention
- Sodium-glucose transport-2 (SGLT-2) inhibitors — drug: Dapagliflozin 10mg in addition to standard clinical care · Standard medical treatment — other: Standard clinical care
- Patient visit burden
- Not specified by the sponsor
In plain English
This study, run by the University of Aberdeen, is looking at whether a medicine called dapagliflozin, a sodium-glucose transporter type 2 (SGLT2) inhibitor, can protect the heart from damage caused by anthracycline chemotherapy in adults with breast cancer. Anthracyclines are chemotherapy drugs that can sometimes harm the heart. Not stated — ask the trial team for full study details.
Who can take part
- Adults aged 18 to 70 with breast cancer
- Due to have anthracycline chemotherapy (before or after surgery)
- Low or medium risk of heart problems, based on blood tests, heart scans and lifestyle checks
- Able to give written informed consent
- Able to read and understand English
Who may not be able to
- Known intolerance to dapagliflozin
- High risk of heart problems
- Significant kidney problems
- Any previous cancer diagnosis
- Known type 1 or type 2 diabetes
- Unable to have magnetic resonance imaging (MRI) scans
- Previous treatment with anthracyclines
- Unable to read and understand English
- Pregnancy
What taking part involves
- • Taking dapagliflozin (an SGLT2 inhibitor medicine) alongside anthracycline chemotherapy
- • Heart checks are likely to include blood tests and heart scans, including magnetic resonance imaging (MRI) — exact details not stated, ask the trial team
Time commitment: Not stated — ask the trial team about how many visits there are, how long the study lasts, and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 18 Years to 70 Years
- Who
- Female
- Number of participants
- 70
- Started
- 2025-12-12
- Last checked
- 2025-07
Plain English Summary
What is this study?
- • Testing a new treatment for breast cancer
- • NA - 70 participants
- • Cardiotoxicity is heart damage that arises from certain drugs, such as those used for cancer treatment and develops in approximately 10% of patients with breast cancer who are treated with anthracyclines
Who can take part?
- • Ages 18 Years to 70 Years
- • Diagnosed with breast cancer
- • Female only
Where?
- • Aberdeen - Cardiac Research Office, Aberdeen Royal Infirmary
- • Aberdeen - University of Aberdeen
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Cardiotoxicity is heart damage that arises from certain drugs, such as those used for cancer treatment and develops in approximately 10% of patients with breast cancer who are treated with anthracyclines. It has been suggested that sodium-glucose transporter-2 (SGLT2) inhibitors may reduce the damage to the heart caused by anthracycline chemotherapy. The investigators wish to determine whether dapagliflozin (SGLT2 inhibitor) taken daily during chemotherapy will reduce the rate of cardiotoxicity.
More detail
Cardiac dysfunction is a major complication of cancer drug therapies, affecting approximately 10% of patients treated with anthracyclines. It has the worst prognosis of all cardiomyopathies and is currently thought to be a consequence of an energetic based mitochondrial dysfunction. This energy deficit could potentially be ameliorated by the putative cardiometabolic benefits of sodium-glucose transporter type 2 inhibition. In pilot data from patients with breast cancer, the investigators have demonstrated that cardiac magnetic resonance spectroscopy can identify and quantify the myocardial energetic deficit associated with anthracycline therapy. The purpose of this study is to determine whether sodium-glucose transporter type 2 inhibition has the potential to reverse the myocardial energetic deficit associated with anthracycline toxicity.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years - 70 Years
- Who can join: Female only
What the study is looking for
- ✓Patients with breast cancer between 18-70 years of age.
- ✓Patients with low to medium cardiovascular risk.
- ✓Patients scheduled for after surgery or neo-after surgery anthracycline therapy.
- ✓Patients who are able to give written agreement to take part to take part in the study.
- ✓Patients who can read and understand English.
Who cannot take part
- ✗Patients with a known intolerance of dapagliflozin
- ✗Patients with high cardiovascular risk as specified by the most recent cardio-oncology guidelines.
- ✗Patients with significant kidney impairment (estimated glomerular filtration rate \<45 mL/min/1.73 m2).
- ✗Patients with a previous cancer diagnosis.
- ✗Patients with known type 1 or 2 diabetes mellitus. We will not actively screen for diabetes. This is not done in...
See the full criteria
Where Is This Study? (2 UK sites)
Cardiac Research Office, Aberdeen Royal Infirmary
Aberdeen AB25 2ZD, United Kingdom
University of Aberdeen
Aberdeen AB25 2ZD, United Kingdom
How to Get in Touch
Sylvia Kamya, MBChB
Sponsor contactCONTACT
Amelia Rudd, PhD
Sponsor contactCONTACT